Latest Financial Position News

Alpha HPA Limited reported a 135% revenue increase but a 31% rise in net loss for FY2026, while progressing its Stage Two facility on schedule with robust customer demand exceeding 12,000 tonnes per annum under letters of intent.

Genetic Technologies Limited slashed its net loss by nearly 88% in FY2025 following a Deed of Company Arrangement and exit from voluntary administration, pivoting to a corporate office model after selling its operating businesses.

Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.

Wildcat Resources has delivered robust lithium assay results from its Bolt Cutter Central discovery and Tabba Tabba project, while tripling its exploration strike length through a strategic tenement rights acquisition.

Way2VAT Ltd surged revenue by 61% to A$4 million in H1 FY26, driven by client growth and its new AI e-invoicing platform. However, losses widened sharply, prompting cost cuts and debt facility extensions to sustain operations.

Carma Limited posted a 59% revenue jump to $113.8 million in FY26, doubling gross profit to $10.5 million, while gearing up to double reconditioning capacity and target positive EBITDA in 2027.

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

PT ANTAM (ASX:ATM) posted a 6% increase in net sales to Rp62.71 trillion in the first half of 2026, driven by steady gold, nickel, and bauxite sales. Profit after tax surged 34% to Rp6.91 trillion, supported by improved margins and foreign exchange gains.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Enprise Group reported a $2.2 million net loss for FY2026 amid rising revenue and cost pressures, prompting a strategic reset aimed at returning to profitability in FY2027.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Michael Hill International reported a 1.9% revenue increase to $655.7 million in FY26, with comparable EBIT up 57% to $24 million and net profit soaring 376%. The company restored dividends and announced a Chair succession.